BRPI0908602A2 - método e composição farmacêutica para o tratamento de doenças autoimunes. - Google Patents

método e composição farmacêutica para o tratamento de doenças autoimunes.

Info

Publication number: BRPI0908602A2
Authority: BR; Brazil
Prior art keywords: treatment; composition; autoimmune diseases; pharmaceutical method; pharmaceutical
Prior art date: 2008-03-27

Application number

BRPI0908602A

Other languages

English (en)

Inventor

Shiozawa Shunichi

Aikawa Yukihiko

Original Assignee

Toyama Chemical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-27

Filing date

2009-03-25

Publication date

2019-09-24

2009-03-25 Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd

2019-09-24 Publication of BRPI0908602A2 publication Critical patent/BRPI0908602A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI0908602A 2008-03-27 2009-03-25 método e composição farmacêutica para o tratamento de doenças autoimunes. BRPI0908602A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008083730		2008-03-27
PCT/JP2009/055930 WO2009119652A1 (ja)	2008-03-27	2009-03-25	ベンゾフェノン誘導体またはその塩およびＴＮＦα阻害剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物

Publications (1)

Publication Number	Publication Date
BRPI0908602A2 true BRPI0908602A2 (pt)	2019-09-24

Family

ID=41113843

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908602A BRPI0908602A2 (pt)	2008-03-27	2009-03-25	método e composição farmacêutica para o tratamento de doenças autoimunes.

Country Status (22)

Country	Link
US (1)	US20110020366A1 (pt)
EP (1)	EP2258361B1 (pt)
JP (1)	JP5512510B2 (pt)
KR (1)	KR20100129305A (pt)
CN (1)	CN101980705B (pt)
AU (1)	AU2009229973B2 (pt)
BR (1)	BRPI0908602A2 (pt)
CA (1)	CA2719290A1 (pt)
CY (1)	CY1115641T1 (pt)
DK (1)	DK2258361T3 (pt)
ES (1)	ES2507086T3 (pt)
HR (1)	HRP20140961T1 (pt)
IL (1)	IL208121A0 (pt)
MX (1)	MX2010010440A (pt)
NZ (1)	NZ588128A (pt)
PL (1)	PL2258361T3 (pt)
PT (1)	PT2258361E (pt)
RU (1)	RU2522272C2 (pt)
SG (1)	SG188816A1 (pt)
SI (1)	SI2258361T1 (pt)
WO (1)	WO2009119652A1 (pt)
ZA (1)	ZA201006585B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009040952A1 (ja)	2007-09-28	2009-04-02	Toyama Chemical Co., Ltd.	ベンゾフェノン誘導体またはその塩を含有する薬剤
CN118252824B (zh) *	2024-01-25	2024-09-17	中国医学科学院阜外医院	化合物用于治疗射血分数保留的心衰的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO123430B1 (ro) *	2001-11-16	2012-04-30	Toyama Chemical Co., Ltd.	Derivaţi noi de benzofenonă sau sărurile acestora
MY150740A (en) *	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004060911A2 (en) *	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
US7569689B2 (en) *	2004-01-16	2009-08-04	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1988085B8 (en) *	2006-02-21	2015-01-28	Toyama Chemical Co., Ltd.	Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
EP2022497B1 (en) *	2006-05-26	2014-04-30	Toyama Chemical Co., Ltd.	Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof
CA2652939C (en) *	2006-05-26	2014-12-02	Kenji Yonezawa	Novel crystal of 3-[5-[4-(cyclopentyloxy)-2- hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionic acid
WO2009040952A1 (ja) *	2007-09-28	2009-04-02	Toyama Chemical Co., Ltd.	ベンゾフェノン誘導体またはその塩を含有する薬剤

2009
- 2009-03-25 PL PL09724165T patent/PL2258361T3/pl unknown
- 2009-03-25 ES ES09724165.7T patent/ES2507086T3/es active Active
- 2009-03-25 MX MX2010010440A patent/MX2010010440A/es active IP Right Grant
- 2009-03-25 AU AU2009229973A patent/AU2009229973B2/en not_active Ceased
- 2009-03-25 CA CA2719290A patent/CA2719290A1/en not_active Abandoned
- 2009-03-25 RU RU2010143895/15A patent/RU2522272C2/ru not_active IP Right Cessation
- 2009-03-25 WO PCT/JP2009/055930 patent/WO2009119652A1/ja not_active Ceased
- 2009-03-25 CN CN2009801110519A patent/CN101980705B/zh not_active Expired - Fee Related
- 2009-03-25 SG SG2013014394A patent/SG188816A1/en unknown
- 2009-03-25 BR BRPI0908602A patent/BRPI0908602A2/pt not_active IP Right Cessation
- 2009-03-25 HR HRP20140961AT patent/HRP20140961T1/hr unknown
- 2009-03-25 JP JP2010505719A patent/JP5512510B2/ja not_active Expired - Fee Related
- 2009-03-25 KR KR1020107021101A patent/KR20100129305A/ko not_active Ceased
- 2009-03-25 DK DK09724165.7T patent/DK2258361T3/da active
- 2009-03-25 EP EP09724165.7A patent/EP2258361B1/en not_active Not-in-force
- 2009-03-25 SI SI200931084T patent/SI2258361T1/sl unknown
- 2009-03-25 PT PT97241657T patent/PT2258361E/pt unknown
- 2009-03-25 US US12/934,572 patent/US20110020366A1/en not_active Abandoned
- 2009-03-25 NZ NZ588128A patent/NZ588128A/xx not_active IP Right Cessation
2010
- 2010-09-13 IL IL208121A patent/IL208121A0/en unknown
- 2010-09-14 ZA ZA2010/06585A patent/ZA201006585B/en unknown
2014
- 2014-10-10 CY CY20141100825T patent/CY1115641T1/el unknown

Also Published As

Publication number	Publication date
AU2009229973A1 (en)	2009-10-01
IL208121A0 (en)	2010-12-30
JP5512510B2 (ja)	2014-06-04
HRP20140961T1 (hr)	2014-11-21
RU2522272C2 (ru)	2014-07-10
WO2009119652A1 (ja)	2009-10-01
CA2719290A1 (en)	2009-10-01
KR20100129305A (ko)	2010-12-08
SI2258361T1 (sl)	2015-01-30
ZA201006585B (en)	2011-11-30
MX2010010440A (es)	2010-12-15
RU2010143895A (ru)	2012-05-10
PT2258361E (pt)	2014-10-15
EP2258361A1 (en)	2010-12-08
SG188816A1 (en)	2013-04-30
US20110020366A1 (en)	2011-01-27
ES2507086T3 (es)	2014-10-14
CN101980705A (zh)	2011-02-23
EP2258361B1 (en)	2014-09-17
JPWO2009119652A1 (ja)	2011-07-28
AU2009229973B2 (en)	2013-10-10
CN101980705B (zh)	2012-11-07
EP2258361A4 (en)	2012-01-04
CY1115641T1 (el)	2017-01-04
PL2258361T3 (pl)	2015-02-27
DK2258361T3 (da)	2014-10-27
NZ588128A (en)	2012-12-21

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI1015569A2 (pt)	2016-08-16	compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
HUE049880T2 (hu)	2020-10-28	Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
PT2367561E (pt)	2015-10-23	Composições e métodos para o tratamento da doença celíaca
ES2525801T8 (es)	2018-03-20	Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
BRPI0909179A2 (pt)	2015-08-25	Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
BRPI1013705A2 (pt)	2016-04-05	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0921321A2 (pt)	2018-10-16	métodos para o tratamento de indwcções e tumores
BRPI0919288A2 (pt)	2015-12-15	teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0816784A2 (pt)	2015-03-24	Fatores neuro-endócrinos para o tratamento de doenças degenerativas
PL2442814T3 (pl)	2019-04-30	Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
BRPI0911612A2 (pt)	2015-12-15	composições e métodos para o tratamento da esclerose múltipla.
PT2894165T (pt)	2023-03-17	Métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0917444A2 (pt)	2015-12-01	composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
BRPI0917358A2 (pt)	2015-11-17	formulação farmacêutica de liberação controlada e método.
BRPI1009920A2 (pt)	2016-03-15	composições bacterianas para profilaxina e tratamento de doença degenerativa.
CR11019A (es)	2009-10-20	3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0916862A2 (pt)	2016-02-10	compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI0909180A2 (pt)	2016-08-09	composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI1013559A2 (pt)	2016-04-12	compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
BRPI0909048A2 (pt)	2015-11-24	composição farmacêutica, e, método de tratamento de uma doença autoimune
CY2016053I2 (el)	2017-06-28	Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0911577A2 (pt)	2016-01-05	derivados espiro-indol para o tratamento de doenças parasíticas.